$
4.360
-0.11(-2.461%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.480
Open
4.450
VWAP
4.33
Vol
34.52K
Mkt Cap
11.15B
Low
4.250
Amount
149.42K
EV/EBITDA(TTM)
--
Total Shares
79.94M
EV
6.43M
EV/OCF(TTM)
--
P/S(TTM)
0.49
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
892.67K
-92.4%
--
--
776.67K
-84.29%
--
--
661.33K
-87.74%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by -12.74% over the past three months. During the same period, the stock price has changed by 50.34%.
Revenue Estimates for FY2025
Revise Downward
down Image
-12.74%
In Past 3 Month
Stock Price
Go Up
up Image
+50.34%
In Past 3 Month
2 Analyst Rating
up Image
335.78% Upside
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 19.00 USD with a low forecast of 12.00 USD and a high forecast of 26.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
335.78% Upside
Current: 4.360
sliders
Low
12.00
Averages
19.00
High
26.00
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
2025-04-02
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$9 → $26
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$21 → $9
2024-11-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2024-11-06
Reason
Jones Trading
Justin Walsh
Strong Buy
Initiates
$2
2024-09-04
Reason

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -2.70, compared to its 5-year average forward P/E of -1.43. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.43
Current PE
-2.70
Overvalued PE
0.10
Undervalued PE
-2.97

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.05
Undervalued EV/EBITDA
-2.52

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.79
Current PS
4.95
Overvalued PS
56.29
Undervalued PS
-30.70

Financials

Annual
Quarterly
FY2025Q1
YoY :
-96.28%
255.00K
Total Revenue
FY2025Q1
YoY :
-50.41%
-2.39M
Operating Profit
FY2025Q1
YoY :
-836.64%
5.13M
Net Income after Tax
FY2025Q1
0.00
EPS - Diluted
FY2025Q1
YoY :
-81.68%
-2.59M
Free Cash Flow
FY2025Q1
YoY :
+10.03%
86.67
Gross Profit Margin - %
FY2025Q1
-144.93
FCF Margin - %
FY2025Q1
YoY :
-19908.77%
2.01K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

BLRX News & Events

Events Timeline

2025-05-30 (ET)
2025-05-30
08:43:01
BioLineRx upgraded to Buy from Hold at JonesResearch
select
2025-05-30
07:05:01
BioLineRx announces new data from Phase 2 combination trial of motixafortide
select
2025-05-27 (ET)
2025-05-27
07:03:06
BioLineRx reports Q1 EPS 0c vs. 0c last year
select
Sign Up For More Events

News

4.0
05-31NASDAQ.COM
Jones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)
4.5
05-30Benzinga
Dow Edges Higher; Dell Shares Fall After Q1 Results
9.0
05-30Benzinga
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
Sign Up For More News

FAQ

arrow icon

What is BioLine RX Ltd (BLRX) stock price today?

The current price of BLRX is 4.36 USD — it has decreased -2.46 % in the last trading day.

arrow icon

What is BioLine RX Ltd (BLRX)'s business?

arrow icon

What is the price predicton of BLRX Stock?

arrow icon

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

arrow icon

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for BioLine RX Ltd (BLRX)'s fundamentals?

arrow icon

How many employees does BioLine RX Ltd (BLRX). have?

arrow icon

What is BioLine RX Ltd (BLRX) market cap?